Drug Profile
CAP 2003
Alternative Names: CAP-2003; CDC-exosomesLatest Information Update: 10 Apr 2023
Price :
$50
*
At a glance
- Originator Capricor Therapeutics
- Developer Capricor Therapeutics; Cedars-Sinai Health System
- Class Anti-inflammatories; Antifibrotics; Cardiovascular therapies; Exosome therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
- No development reported Cardiovascular disorders; Fibrosis; Graft-versus-host disease; Inflammation
Most Recent Events
- 10 Apr 2023 CAP 2003 is still in preclinical trials for Duchhene Muscular dystrophy (Capricor Therapeutics pipeline, April 2023)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (Parenteral)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Fibrosis in USA (Parenteral)